EQUITY RESEARCH MEMO

Surgical Planning Associates

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)65/100

Surgical Planning Associates (SPA) is a privately held medical device and digital health company headquartered in Cambridge, Massachusetts. Founded in 2015, SPA developed the HipInsight™ system, the world’s first mixed reality-based digital surgery platform for total hip arthroplasty. The system provides surgeons with real-time “x-ray vision,” overlaying anatomical structures, instruments, and implant positions onto the patient’s body during surgery. This technology aims to improve the accuracy and efficiency of hip replacement procedures while reducing complications and revision rates. SPA operates at the intersection of augmented reality, surgical navigation, and orthopedics, targeting a large and growing global market for hip arthroplasty, which is driven by aging populations and increasing demand for minimally invasive surgery. The company’s solution offers a competitive advantage over traditional navigation and robotic systems by being less invasive, more intuitive, and potentially lower cost. While SPA is still in the early commercial stages, the platform has demonstrated strong clinical potential. The mixed reality approach eliminates the need for pre-operative CT scans in many cases, streamlining the surgical workflow. With no disclosed funding rounds or valuation, SPA likely remains bootstrap or early venture-backed. The key near-term milestones include regulatory approvals in additional geographies, securing strategic partnerships with hospital systems, and generating peer-reviewed clinical evidence. If successful, HipInsight could become a standard tool in hip arthroplasty, disrupting the orthopedic navigation market.

Upcoming Catalysts (preview)

  • Q4 2026FDA 510(k) clearance for expanded indications (e.g., direct anterior approach)70% success
  • 2027Partnership with major hospital network or group purchasing organization60% success
  • Q2 2027Publication of pivotal clinical trial results showing improved outcomes vs. standard technique75% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)